Risk factors
Lisata Therapeutics (LSTA) risk factors
Item 1A of every Lisata Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors82 risks7 new5 dropped12 reworded
Lisata added a merger agreement risk with Kuva and updated going concern warnings. Cash reserves stand at $16.0 million.
Filed Mar 12, 2026 - FY2024 10-K risk factors80 risks
Lisata Therapeutics faces continuous net losses and significant future capital needs to fund ongoing clinical trials. The company depends on the clinical success and commercialization of its lead product candidate, certepetide. Operations rely heavily on third-party contract manufacturers and foreign research collaborations without internal commercial infrastructure.
Filed Feb 27, 2025